Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

ESMO 2024

13 - 17 Sep 2024
Barcelona, Spain
Videos
News
ESMO 2024: Encoradenib & binimetinib shows long-term clinically meaningful response in patients with BRAF V600E-mutant metastatic non-small Cell lung cancer
ESMO 2024: Encoradenib & binimetinib shows long-term clinically meaningful response in patients with BRAF V600E...
ESMO 2024: Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
ESMO 2024: Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to...
ESMO 2024: Alternating pazopanib bevacizumab regimen doubles progression-free survival in metastatic kidney cancer
ESMO 2024: Alternating pazopanib bevacizumab regimen doubles progression-free survival in metastatic kidney cancer
ESMO 2024: Immunotherapy shows promise for men with specific types of prostate cancer
ESMO 2024: Immunotherapy shows promise for men with specific types of prostate cancer
ESMO 2024: Survival benefits from adding perioperative durvalumab to chemo in MIBC
ESMO 2024: Survival benefits from adding perioperative durvalumab to chemo in MIBC
ESMO 2024: High dose vitamin D3 does not provide benefit for metastatic colorectal cancer
ESMO 2024: High dose vitamin D3 does not provide benefit for metastatic colorectal cancer
ESMO 2024: Coaching programme for increased exercise in breast cancer patients
ESMO 2024: Coaching programme for increased exercise in breast cancer patients
ESMO 2024: Immunotherapy benefits for early stage gynaecological cancer
ESMO 2024: Immunotherapy benefits for early stage gynaecological cancer
ESMO 2024: Immunotherapy improves long-term survival in growing number of cancers
ESMO 2024: Immunotherapy improves long-term survival in growing number of cancers
ESMO 2024: Combination therapy reduced agitated delirium in patients with advanced cancers
ESMO 2024: Combination therapy reduced agitated delirium in patients with advanced cancers
ESMO 2024: Novel ADC AZD8205 demonstrates manageable safety profile and preliminary efficacy in first-in-human trial
ESMO 2024: Novel ADC AZD8205 demonstrates manageable safety profile and preliminary efficacy in first-in-human...
ESMO 2024: Breastfeeding after breast cancer is safe
ESMO 2024: Breastfeeding after breast cancer is safe
ESMO 2024: Repeat immune checkpoint inhibitor therapy not recommended for advanced kidney cancer
ESMO 2024: Repeat immune checkpoint inhibitor therapy not recommended for advanced kidney cancer
ESMO 2024: Trastuzumab deruxtecan effective against brain mets in HER2-positive breast cancer
ESMO 2024: Trastuzumab deruxtecan effective against brain mets in HER2-positive breast cancer
ESMO 2024: Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase 1 trial
ESMO 2024: Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase 1 trial
ESMO 2024: Long-course radiotherapy is better than short-course for organ preservation in rectal cancer
ESMO 2024: Long-course radiotherapy is better than short-course for organ preservation in rectal cancer
ESMO 2024: Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal
ESMO 2024: Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone...

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation